Klein Eric A, Thompson Ian M, Lippman Scott M, Goodman Phyllis J, Albanes Demetrius, Taylor Philip R, Coltman Charles
Section of Urologic Oncology, Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA.
Urol Oncol. 2003 Jan-Feb;21(1):59-65. doi: 10.1016/s1078-1439(02)00301-0.
Growing evidence suggests that both selenium and vitamin E may reduce the risk of prostate cancer. SELECT is a randomized, prospective, double-blind study designed to determine if selenium and vitamin E can reduce the risk of prostate cancer among healthy men.
The preclinical and epidemiologic evidence regarding chemoprevention with selenium and vitamin E were reviewed. Secondary analyses from randomized trials of both agents were included in the analysis. Data from these analyses as well as evidence from the Prostate Cancer Prevention Trial were used to develop the schema of SELECT.
Preclinical, epidemiologic, and Phase III data suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. The experience of the Prostate Cancer Prevention Trial and the rapid accrual of SELECT during its first year demonstrate the interest and dedication of healthy men to long-term studies of cancer prevention. A total of 32,400 men are planned to be randomized in SELECT.
SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.
越来越多的证据表明，硒和维生素E都可能降低前列腺癌的风险。SELECT是一项随机、前瞻性、双盲研究，旨在确定硒和维生素E能否降低健康男性患前列腺癌的风险。
回顾了关于硒和维生素E化学预防的临床前和流行病学证据。分析纳入了这两种药物随机试验的二次分析。这些分析的数据以及前列腺癌预防试验的证据被用于制定SELECT的方案。
临床前、流行病学和III期数据表明，硒和维生素E在前列腺癌预防方面都有潜在疗效。前列腺癌预防试验的经验以及SELECT在第一年的快速入组表明了健康男性对癌症预防长期研究的兴趣和投入。SELECT计划总共随机分配32400名男性。
SELECT是第二项前列腺癌化学预防的大规模研究。2001年开始招募受试者，预计2013年得出最终结果。
